Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs targeting protein-protein interactions.

Patrick Chène1

  • 1Oncology Research, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. patrick_chene@yahoo.com

Chemmedchem
|August 8, 2006
PubMed
Summary

Identifying and targeting protein interfaces is crucial for developing new therapeutics against diseases. This study explores the properties of protein interfaces as potential drug targets to inhibit harmful protein-protein interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter.

Journal of medicinal chemistry·2026
Same author

Study of the TEAD-binding domain of the VGLL1, VGLL2 and VGLL3 proteins from vertebrates.

Archives of biochemistry and biophysics·2024
Same author

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Nature cancer·2024
Same author

Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge.

ChemMedChem·2024
Same author

mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B.

ACS chemical biology·2024
Same author

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Nature cancer·2024

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Protein-protein interactions are fundamental to biological processes and implicated in numerous human diseases.
  • Targeting these interactions with small molecules offers a promising therapeutic strategy.
  • However, protein interfaces present challenges for small-molecule drug development due to their evolutionary divergence from enzyme active sites.

Purpose of the Study:

  • To discuss the properties of protein interfaces relevant to their use as drug targets.
  • To highlight the challenges and opportunities in developing small molecules that inhibit protein-protein interactions.
  • To explore strategies for identifying and exploiting druggable protein interfaces.

Main Methods:

  • Review and analysis of the structural diversity of protein-protein interaction interfaces.
  • Evaluation of the suitability of different interface types for small-molecule binding.
  • Discussion of medicinal chemistry approaches for targeting protein interfaces.

Main Results:

  • Protein interfaces exhibit significant structural diversity, with some being more amenable to small-molecule inhibition than others.
  • Enzyme catalytic sites are generally more evolved for small-molecule binding than protein-protein interaction interfaces.
  • Identifying and characterizing 'druggable' protein interfaces is a key challenge in drug discovery.

Conclusions:

  • Protein interfaces represent a largely untapped resource for novel drug targets.
  • Understanding the specific properties of protein interfaces is essential for successful drug design.
  • Further research into identifying and optimizing inhibitors for protein-protein interactions is warranted for therapeutic advancement.

Related Experiment Videos